Advertisement

Psychotic Bipolar Disorder

  • Massimiliano Buoli
  • Alice Caldiroli
Chapter

Abstract

Psychotic symptoms are considered a clinical predictor of poor outcome in bipolar disorder (BD). The misdiagnosis of psychotic BD (BD-P) with schizophrenia, schizoaffective disorder, or delusional disorder is very common. The identification of biological markers for BD-P would contribute to establish an early diagnosis and to define a proper treatment, to improve outcome of BD-P patients.

A case of a patient suffering from BD-P has been described, focusing on neuroimaging, neuropsychological, and inflammation data that could be considered potential biomarkers of BD-P.

The patient was a 36-year-old female. During her two hospitalizations, inflammatory and metabolic markers were all normal, except for lower plasma levels of vitamin A. After giving her written informed consent, epigenetic tests were performed, showing a significantly different expression of some miRNAs than healthy controls (HC). The magnetic resonance imaging (MRI) showed hypoplasia of the cerebellar vermis and a small left peritrigonal area of hyperintensity in T2 sequence. The only neuropsychological deficit appeared in the motor task. The positron emission tomography (PET) showed a bilateral hypermetabolism in the frontal cortex, cingulate, and striatum.

This case demonstrated that biological markers may be useful to predict outcome of psychotic bipolar patients.

Keywords

Bipolar disorder Psychotic symptoms Biomarkers 

References

  1. 1.
    Fagiolini A, Forgione R, Maccari M, et al. Prevalence, chronicity, burden and borders of bipolar disorder. J Affect Disord. 2013;148:161–9.CrossRefGoogle Scholar
  2. 2.
    Dickerson F, Stallings C, Origoni A, et al. A combined marker of inflammation in individuals with mania. PLoS One. 2013;e73520:8.Google Scholar
  3. 3.
    Goldstein BI, Young LT. Toward clinically applicable biomarkers in bipolar disorder: focus on BDNF, inflammatory markers, and endothelial function. Curr Psychiatry Rep. 2013;15:425.CrossRefGoogle Scholar
  4. 4.
    Frey BN, Andreazza AC, Houenou J, et al. Biomarkers in bipolar disorder: a positional paper from the International Society for Bipolar Disorders Biomarkers Task Force. Aust N Z J Psychiatry. 2013;47:321–32.CrossRefGoogle Scholar
  5. 5.
    Schroeter ML, Sacher J, Steiner J, et al. Serum S100B represents a new biomarker for mood disorders. Curr Drug Targets. 2013;14:1237–48.CrossRefGoogle Scholar
  6. 6.
    Brugue E, Colom F, Sanchez-Moreno J, et al. Depression subtypes in bipolar I and II disorders. Psychopathology. 2008;41:111–4.CrossRefGoogle Scholar
  7. 7.
    Mantere O, Suominen K, Leppämäki S, et al. The clinical characteristics of DSM-IV bipolar I and II disorders: baseline findings from the Jorvi bipolar study (JoBS). Bipolar Disord. 2004;6:395–405.CrossRefGoogle Scholar
  8. 8.
    Keck PE Jr, McElroy SL, Havens JR, et al. Psychosis in bipolar disorder: phenomenology and impact on morbidity and course of illness. Compr. Psychiatry. 2003;44:263–9.Google Scholar
  9. 9.
    Zenisek R, Thaler N, Ringdahl E, et al. C-29Intellectual ability and functional outcome in bipolar disorder and schizophrenia. Arch Clin Neuropsychol. 2014;29:582–3.CrossRefGoogle Scholar
  10. 10.
    Østergaard SD, Bertelsen A, Nielsen J, et al. The association between psychotic mania, psychotic depression and mixed affective episodes among 14.529 patients with bipolar disorder. J Affect Disord. 2013;147:44–50.CrossRefGoogle Scholar
  11. 11.
    Vythilingam M, Chen J, Bremner JD, et al. Psychotic depression and mortality. Am J Psychiatry. 2003;160:574–6.CrossRefGoogle Scholar
  12. 12.
    Coryell W, Leon AC, Turvey C, et al. The significance of psychotic features in manic episodes: a report from the NIMH collaborative study. J Affect Disord. 2001;67:79–88.CrossRefGoogle Scholar
  13. 13.
    Kessing LV. Subtypes of manic episodes according to ICD-10: prediction of time to remission and risk of relapse. J Affect Disord. 2004;81:279–85.CrossRefGoogle Scholar
  14. 14.
    Tohen M, Zarate CA Jr, Hennen J, et al. The McLean-Harvard first-episode mania study: prediction of recovery and first recurrence. Am J Psychiatry. 2003;160:2099–107.CrossRefGoogle Scholar
  15. 15.
    Azorin JM, Akiskal H, Hantouche E. The mood-instability hypothesis in the origin of mood-congruent versus mood-incongruent psychotic distinction in mania: validation in a French National Study of 1090 patients. J Affect Disord. 2006;96:215–23.CrossRefGoogle Scholar
  16. 16.
    Kessing LV. Subtypes of depressive episodes according to ICD-10: prediction of risk of relapse and suicide. Psychopathology. 2003;36:285–91.CrossRefGoogle Scholar
  17. 17.
    Buoli M, Caldiroli A, Altamura AC. Psychotic versus non-psychotic major depressive disorder: a comparative naturalistic study. Asian J Psychiatr. 2013;6:333–7.CrossRefGoogle Scholar
  18. 18.
    Altamura AC, Dell’Osso B, Berlin HA, et al. Duration of untreated illness and suicide in bipolar disorder: a naturalistic study. Eur Arch Psychiatry Clin Neurosci. 2010;260:385–91.CrossRefGoogle Scholar
  19. 19.
    Birnbaum HG, Shi L, Dial E, et al. Economic consequences of not recognizing bipolar disorder patients: across-sectional descriptive analysis. J Clin Psychiatry. 2003;64:1201–9.CrossRefGoogle Scholar
  20. 20.
    Altamura AC, Buoli M, Caldiroli A, et al. Misdiagnosis, duration of untreated illness (DUI) and outcome in bipolar patients with psychotic symptoms: a naturalistic study. J Affect Disord. 2015;182:70–5.CrossRefGoogle Scholar
  21. 21.
    Lin A, Reniers RL, Wood SJ. Clinical staging in severe mental disorder: evidence from neurocognition and neuroimaging. Br J Psychiatry Suppl. 2013;54:s11–7.CrossRefGoogle Scholar
  22. 22.
    Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep. 1962;10:799–812.CrossRefGoogle Scholar
  23. 23.
    Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429–35.CrossRefGoogle Scholar
  24. 24.
    Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56.CrossRefGoogle Scholar
  25. 25.
    Buoli M, Caldiroli A, Cumerlato Melter C, et al. Biological aspects and candidate biomarkers for psychotic bipolar disorder: a systematic review. Psychiatry Clin Neurosci. 2016;70:227–44.CrossRefGoogle Scholar
  26. 26.
    Goes FS, Willour VL, Zandi PP, et al. Bipolar disorder Phenome group; NIMH genetics initiative bipolar disorder consortium. Family-based association study of Neuregulin 1 with psychotic bipolar disorder. Am J Med Genet B Neuropsychiatr Genet. 2009;150B:693–702.CrossRefGoogle Scholar
  27. 27.
    Prata DP, Breen G, Osborne S, et al. An association study of the neuregulin 1 gene, bipolar affective disorder and psychosis. Psychiatr Genet. 2009;19:113–6.CrossRefGoogle Scholar
  28. 28.
    Cheng R, Juo SH, Loth JE, et al. Genome-wide linkage scan in a large bipolar disorder sample from the National Institute of Mental Health genetics initiative suggests putative loci for bipolar disorder, psychosis, suicide, and panic disorder. Mol Psychiatry. 2006;11:252–60.CrossRefGoogle Scholar
  29. 29.
    Goes FS, Zandi PP, Miao K, et al. Mood-incongruent psychotic features in bipolar disorder: familial aggregation and suggestive linkage to 2p11-q14 and 13q21-33. Am J Psychiatry. 2007;164:236–47.CrossRefGoogle Scholar
  30. 30.
    Kremeyer B, García J, Müller H, et al. Genome-wide linkage scan of bipolar disorder in a Colombian population isolate replicates loci on chromosomes 7p21-22, 1p31, 16p12 and 21q21-22 and identifies a novel locus on chromosome 12q. Hum Hered. 2010;70:255–68.CrossRefGoogle Scholar
  31. 31.
    Olsson SK, Sellgren C, Engberg G, et al. Cerebrospinal fluid kynurenic acid is associated with manic and psychotic features in patients with bipolar I disorder. Bipolar Disord. 2012;14:719–26.CrossRefGoogle Scholar
  32. 32.
    Johansson AG, Nikamo P, Schalling M, Landén M. Polymorphisms in AKR1C4 and HSD3B2 and differences in serum DHEAS and progesterone are associated with paranoid ideation during mania or hypomania in bipolar disorder. Eur Neuropsychopharmacol. 2012;22:632–40.CrossRefGoogle Scholar
  33. 33.
    Severance EG, Dupont D, Dickerson FB, et al. Immune activation by casein dietary antigens in bipolar disorder. Bipolar Disord. 2010;12:834–42.CrossRefGoogle Scholar
  34. 34.
    Severance EG, Gressitt KL, Yang S, et al. Seroreactive marker for inflammatory bowel disease and associations with antibodies to dietary proteins in bipolar disorder. Bipolar Disord. 2014;16:230–40.CrossRefGoogle Scholar
  35. 35.
    Narayanan B, O’Neil K, Berwise C, et al. Resting state electroencephalogram oscillatory abnormalities in schizophrenia and psychotic bipolar patients and their relatives from the bipolar and schizophrenia network on intermediate phenotypes study. Biol Psychiatry. 2014;76:456–65.CrossRefGoogle Scholar
  36. 36.
    Cabranes JA, Ancín I, Santos JL, et al. P50 sensory gating is a trait marker of the bipolar spectrum. Eur Neuropsychopharmacol. 2013;23:721–7.CrossRefGoogle Scholar
  37. 37.
    Olincy A, Martin L. Diminished suppression of the P50 auditory evoked potential in bipolar disorder subjects with a history of psychosis. Am J Psychiatry. 2005;162:43–9.CrossRefGoogle Scholar
  38. 38.
    Sánchez-Morla EM, García-Jiménez MA, Barabash A, et al. P50 sensory gating deficit is a common marker of vulnerability to bipolar disorder and schizophrenia. Acta Psychiatr Scand. 2008;117:313–8.CrossRefGoogle Scholar
  39. 39.
    Schulze KK, Hall MH, McDonald C, et al. P50 auditory evoked potential suppression in bipolar disorder patients with psychotic features and their unaffected relatives. Biol Psychiatry. 2007;62:121–8.CrossRefGoogle Scholar
  40. 40.
    Carroll CA, Kieffaber PD, Vohs JL, et al. Contributions of spectral frequency analyses to the study of P50 ERP amplitude and suppression in bipolar disorder with or without a history of psychosis. Bipolar Disord. 2008;10:776–87.CrossRefGoogle Scholar
  41. 41.
    Patterson JV, Sandman CA, Ring A, et al. An initial report of a new biological marker for bipolar disorder: P85 evoked brain potential. Bipolar Disord. 2009;11:596–609.CrossRefGoogle Scholar
  42. 42.
    Reite M, Teale P, Rojas DC, et al. Bipolar disorder: anomalous brain asymmetry associated with psychosis. Am J Psychiatry. 1999;156:1159–63.PubMedGoogle Scholar
  43. 43.
    Patterson JV, Sandman CA, Jin Y, et al. Gating of a novel brain potential is associated with perceptual anomalies in bipolar disorder. Bipolar Disord. 2013;15:314–25.CrossRefGoogle Scholar
  44. 44.
    Hamm JP, Ethridge LE, Shapiro JR, et al. Spatiotemporal and frequency domain analysis of auditory paired stimuli processing in schizophrenia and bipolar disorder with psychosis. Psychophysiology. 2012;49:522–30.CrossRefGoogle Scholar
  45. 45.
    Mahon PB, Lee DS, Trinh H, et al. Morphometry of the amygdala in schizophrenia and psychotic bipolar disorder. Schizophr Res. 2015;164:199–202.CrossRefGoogle Scholar
  46. 46.
    Nenadic I, Maitra R, Langbein K, et al. Brain structure in schizophrenia vs. psychotic bipolar I disorder: a VBM study. Schizophr Res. 2015;165:212–9.CrossRefGoogle Scholar
  47. 47.
    Ratnanather JT, Poynton CB, Pisano DV, et al. Morphometry of superior temporal gyrus and planum temporale in schizophrenia and psychotic bipolar disorder. Schizophr Res. 2013;150:476–83.CrossRefGoogle Scholar
  48. 48.
    Ivleva EI, Bidesi AS, Keshavan MS, et al. Gray matter volume as an intermediate phenotype for psychosis: bipolar-schizophrenia network on intermediate phenotypes (B-SNIP). Am J Psychiatry. 2013;170:1285–96.CrossRefGoogle Scholar
  49. 49.
    McDonald C, Bullmore E, Sham P, et al. Regional volume deviations of brain structure in schizophrenia and psychotic bipolar disorder: computational morphometry study. Br J Psychiatry. 2005;186:369–77.CrossRefGoogle Scholar
  50. 50.
    Yüksel C, McCarthy J, Shinn A, et al. Gray matter volume in schizophrenia and bipolar disorder with psychotic features. Schizophr Res. 2012;138:177–82.CrossRefGoogle Scholar
  51. 51.
    Radaelli D, Poletti S, Gorni I, et al. Neural correlates of delusion in bipolar depression. Psychiatry Res. 2014;221:1–5.CrossRefGoogle Scholar
  52. 52.
    Tost H, Ruf M, Schmäl C, et al. Prefrontal-temporal gray matter deficits in bipolar disorder patients with persecutory delusions. J Affect Disord. 2010;120:54–61.CrossRefGoogle Scholar
  53. 53.
    Edmiston EE, Wang F, Kalmar JH, et al. Lateral ventricle volume and psychotic features in adolescents and adults with bipolar disorder. Psychiatry Res. 2011;194:400–2.CrossRefGoogle Scholar
  54. 54.
    Strasser HC, Lilyestrom J, Ashby ER, et al. Hippocampal and ventricular volumes in psychotic and nonpsychotic bipolar patients compared with schizophrenia patients and community control subjects: a pilot study. Biol Psychiatry. 2005;57:633–9.CrossRefGoogle Scholar
  55. 55.
    Daros AR, Ruocco AC, Reilly JL, et al. Facial emotion recognition in first-episode schizophrenia and bipolar disorder with psychosis. Schizophr Res. 2014;153:32–7.CrossRefGoogle Scholar
  56. 56.
    Ruocco AC, Reilly JL, Rubin LH, et al. Emotion recognition deficits in schizophrenia-spectrum disorders and psychotic bipolar disorder: findings from the bipolar-schizophrenia network on intermediate phenotypes (B-SNIP) study. Schizophr Res. 2014;158:105–12.CrossRefGoogle Scholar
  57. 57.
    Thaler NS, Allen DN, Sutton GP, et al. Differential impairment of social cognition factors in bipolar disorder with and without psychotic features and schizophrenia. J Psychiatr Res. 2013;47:2004–10.CrossRefGoogle Scholar
  58. 58.
    Aminoff SR, Hellvin T, Laerber TV, et al. Neurocognitive features in subgroups of bipolar disorder. Bipolar Disord. 2013;15:272–83.CrossRefGoogle Scholar
  59. 59.
    Frydecka D, Eissa AM, Hewedi DH, et al. Impairments of working memory in schizophrenia and bipolar disorder: the effect of history of psychotic symptoms and different aspects of cognitive task demands. Front Behav Neurosci. 2014;8:416.CrossRefGoogle Scholar
  60. 60.
    Simonsen C, Sundet K, Vaskinn A, et al. Neurocognitive dysfunction in bipolar and schizophrenia spectrum disorders depends on history of psychosis rather than diagnostic group. Schizophr Bull. 2011;37:73–83.CrossRefGoogle Scholar
  61. 61.
    Zanelli J, Reichenberg A, Morgan K, et al. Specific and generalized neuropsychological deficits: a comparison of patients with various first-episode psychosis presentations. Am J Psychiatry. 2010;167:78–85.CrossRefGoogle Scholar
  62. 62.
    Ancín I, Cabranes JA, Santos JL, et al. Executive deficits: a continuum schizophrenia-bipolar disorder or specific to schizophrenia? J Psychiatr Res. 2013;47:1564–71.CrossRefGoogle Scholar
  63. 63.
    Savitz J, van der Merwe L, Stein DJ, et al. Neuropsychological status of bipolar I disorder: impact of psychosis. Br J Psychiatry. 2009;194:243–51.CrossRefGoogle Scholar
  64. 64.
    Selva G, Salazar J, Balanzá-Martínez V, et al. Bipolar I patients with and without a history of psychotic symptoms: do they differ in their cognitive functioning? J Psychiatr Res. 2007;41:265–72.CrossRefGoogle Scholar
  65. 65.
    Banala RR, Karnati PR. Vitamin a deficiency: an oxidative stress marker in sodium fluoride (NaF) induced oxidative damage in developing rat brain. Int J Dev Neurosci. 2015;47:298–303.CrossRefGoogle Scholar
  66. 66.
    Gautam M, Agrawal M, Gautam M, et al. Role of antioxidants in generalized anxiety disorder and depression. Indian J Psychiatry. 2012;54:244–7.CrossRefGoogle Scholar
  67. 67.
    Chowdhury MI, Hasan M, Islam MS, et al. Elevated serum MDA and depleted non-enzymatic antioxidants, macro-minerals and trace elements are associated with bipolar disorder. J Trace Elem Med Biol. 2017;39:162–8.CrossRefGoogle Scholar
  68. 68.
    Tamminga CA, Ivleva EI, Keshavan MS, et al. Clinical phenotypes of psychosis in the bipolar-schizophrenia network on intermediate phenotypes (B-SNIP). Am J Psychiatry. 2013;170:1263–74.CrossRefGoogle Scholar
  69. 69.
    Altamura AC, Serati M, Albano A, et al. An epidemiologic and clinical overview of medical and psychopathological comorbidities in major psychoses. Eur Arch Psychiatry Clin Neurosci. 2011;261:489–508.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2019

Authors and Affiliations

  • Massimiliano Buoli
    • 1
  • Alice Caldiroli
    • 1
  1. 1.Department of Psychiatry, Fondazione IRCCS Ca’ Granda Ospedale Maggiore PoliclinicoUniversity of MilanMilanItaly

Personalised recommendations